> top > docs > PubMed:10318905 > annotations

PubMed:10318905 JSONTXT

Annnotations TAB JSON ListView MergeView

PMID_GLOBAL

Id Subject Object Predicate Lexical cue mondo_id
T1 134-137 DiseaseOrPhenotypicFeature denotes MAP 0012041
T2 148-163 DiseaseOrPhenotypicFeature denotes prostate cancer 0008315
T3 254-267 DiseaseOrPhenotypicFeature denotes breast cancer 0004989|0007254
T5 308-323 DiseaseOrPhenotypicFeature denotes prostate cancer 0008315
T6 336-339 DiseaseOrPhenotypicFeature denotes can 0012833
T7 448-451 DiseaseOrPhenotypicFeature denotes MAP 0012041
T8 481-484 DiseaseOrPhenotypicFeature denotes MAP 0012041
T9 643-658 DiseaseOrPhenotypicFeature denotes prostate cancer 0008315
T10 672-675 DiseaseOrPhenotypicFeature denotes MAP 0012041
T11 978-981 DiseaseOrPhenotypicFeature denotes MAP 0012041
T12 1111-1126 DiseaseOrPhenotypicFeature denotes prostate cancer 0008315
T13 1336-1351 DiseaseOrPhenotypicFeature denotes prostate cancer 0008315

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-170 Sentence denotes From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
TextSentencer_T2 171-268 Sentence denotes Overexpression of the HER2/Neu protooncogene has been linked to the progression of breast cancer.
TextSentencer_T3 269-397 Sentence denotes Here we demonstrate that the growth of prostate cancer LNCaP cells can also be increased by the stable transfection of HER2/Neu.
TextSentencer_T4 398-715 Sentence denotes Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level.
TextSentencer_T5 716-937 Sentence denotes Reporter assays and mammalian two-hybrid assays further suggest this HER2/Neu-induced androgen receptor (AR) transactivation may function through the promotion of interaction between AR and AR coactivators, such as ARA70.
TextSentencer_T6 938-1127 Sentence denotes Furthermore, we found this HER2/Neu --> MAP kinase --> AR-ARAs --> PSA pathway could not be blocked completely by hydroxyflutamide, an antiandrogen used in the treatment of prostate cancer.
TextSentencer_T7 1128-1361 Sentence denotes Together, these data provide a novel pathway from HER2/Neu to AR transactivation, and they may represent one of the reasons for the PSA re-elevation and hormone resistance during androgen ablation therapy in prostate cancer patients.
T1 0-170 Sentence denotes From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
T2 171-268 Sentence denotes Overexpression of the HER2/Neu protooncogene has been linked to the progression of breast cancer.
T3 269-397 Sentence denotes Here we demonstrate that the growth of prostate cancer LNCaP cells can also be increased by the stable transfection of HER2/Neu.
T4 398-715 Sentence denotes Using AG879, a HER2/Neu inhibitor, and PD98059, a MAP kinase inhibitor, as well as MAP kinase phosphatase-1 (MPK-1), in the transfection assay, we found that HER2/Neu could induce prostate-specific antigen (PSA), a marker for the progression of prostate cancer, through the MAP kinase pathway at a low androgen level.
T5 716-937 Sentence denotes Reporter assays and mammalian two-hybrid assays further suggest this HER2/Neu-induced androgen receptor (AR) transactivation may function through the promotion of interaction between AR and AR coactivators, such as ARA70.
T6 938-1127 Sentence denotes Furthermore, we found this HER2/Neu --> MAP kinase --> AR-ARAs --> PSA pathway could not be blocked completely by hydroxyflutamide, an antiandrogen used in the treatment of prostate cancer.
T7 1128-1361 Sentence denotes Together, these data provide a novel pathway from HER2/Neu to AR transactivation, and they may represent one of the reasons for the PSA re-elevation and hormone resistance during androgen ablation therapy in prostate cancer patients.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
10318905-6#132#135#gene354 1260-1263 gene354 denotes PSA
10318905-0#32#49#gene367 32-49 gene367 denotes androgen receptor
10318905-0#134#137#gene27352 134-137 gene27352 denotes MAP
10318905-0#148#163#diseaseC0376358 148-163 diseaseC0376358 denotes prostate cancer
10318905-0#148#163#diseaseC0600139 148-163 diseaseC0600139 denotes prostate cancer
10318905-0#148#163#diseaseC0376358 148-163 diseaseC0376358 denotes prostate cancer
10318905-0#148#163#diseaseC0600139 148-163 diseaseC0600139 denotes prostate cancer
10318905-1#22#26#gene2064 193-197 gene2064 denotes HER2
10318905-1#83#96#diseaseC0006142 254-267 diseaseC0006142 denotes breast cancer
10318905-1#83#96#diseaseC0678222 254-267 diseaseC0678222 denotes breast cancer
10318905-2#119#123#gene2064 388-392 gene2064 denotes HER2
10318905-2#39#54#diseaseC0376358 308-323 diseaseC0376358 denotes prostate cancer
10318905-2#39#54#diseaseC0600139 308-323 diseaseC0600139 denotes prostate cancer
10318905-3#109#114#gene1843 507-512 gene1843 denotes MPK-1
10318905-3#245#260#diseaseC0376358 643-658 diseaseC0376358 denotes prostate cancer
10318905-3#245#260#diseaseC0600139 643-658 diseaseC0600139 denotes prostate cancer
10318905-6#208#223#diseaseC0376358 1336-1351 diseaseC0376358 denotes prostate cancer
10318905-6#208#223#diseaseC0600139 1336-1351 diseaseC0600139 denotes prostate cancer
32#49#gene367148#163#diseaseC0376358 10318905-0#32#49#gene367 10318905-0#148#163#diseaseC0376358 associated_with androgen receptor,prostate cancer
32#49#gene367148#163#diseaseC0600139 10318905-0#32#49#gene367 10318905-0#148#163#diseaseC0600139 associated_with androgen receptor,prostate cancer
32#49#gene367148#163#diseaseC0376358 10318905-0#32#49#gene367 10318905-0#148#163#diseaseC0376358 associated_with androgen receptor,prostate cancer
32#49#gene367148#163#diseaseC0600139 10318905-0#32#49#gene367 10318905-0#148#163#diseaseC0600139 associated_with androgen receptor,prostate cancer
134#137#gene27352148#163#diseaseC0376358 10318905-0#134#137#gene27352 10318905-0#148#163#diseaseC0376358 associated_with MAP,prostate cancer
134#137#gene27352148#163#diseaseC0600139 10318905-0#134#137#gene27352 10318905-0#148#163#diseaseC0600139 associated_with MAP,prostate cancer
134#137#gene27352148#163#diseaseC0376358 10318905-0#134#137#gene27352 10318905-0#148#163#diseaseC0376358 associated_with MAP,prostate cancer
134#137#gene27352148#163#diseaseC0600139 10318905-0#134#137#gene27352 10318905-0#148#163#diseaseC0600139 associated_with MAP,prostate cancer
22#26#gene206483#96#diseaseC0006142 10318905-1#22#26#gene2064 10318905-1#83#96#diseaseC0006142 associated_with HER2,breast cancer
22#26#gene206483#96#diseaseC0678222 10318905-1#22#26#gene2064 10318905-1#83#96#diseaseC0678222 associated_with HER2,breast cancer
119#123#gene206439#54#diseaseC0376358 10318905-2#119#123#gene2064 10318905-2#39#54#diseaseC0376358 associated_with HER2,prostate cancer
119#123#gene206439#54#diseaseC0600139 10318905-2#119#123#gene2064 10318905-2#39#54#diseaseC0600139 associated_with HER2,prostate cancer
109#114#gene1843245#260#diseaseC0376358 10318905-3#109#114#gene1843 10318905-3#245#260#diseaseC0376358 associated_with MPK-1,prostate cancer
109#114#gene1843245#260#diseaseC0600139 10318905-3#109#114#gene1843 10318905-3#245#260#diseaseC0600139 associated_with MPK-1,prostate cancer
132#135#gene354208#223#diseaseC0376358 10318905-6#132#135#gene354 10318905-6#208#223#diseaseC0376358 associated_with PSA,prostate cancer
132#135#gene354208#223#diseaseC0600139 10318905-6#132#135#gene354 10318905-6#208#223#diseaseC0600139 associated_with PSA,prostate cancer

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T603 32-49 gene:367 denotes androgen receptor
T604 148-163 disease:C0376358 denotes prostate cancer
T605 134-137 gene:27352 denotes MAP
T606 193-197 gene:2064 denotes HER2
T607 254-267 disease:C0006142 denotes breast cancer
T608 388-392 gene:2064 denotes HER2
T609 308-323 disease:C0376358 denotes prostate cancer
T610 507-512 gene:1843 denotes MPK-1
T611 643-658 disease:C0376358 denotes prostate cancer
T612 1260-1263 gene:354 denotes PSA
T613 1336-1351 disease:C0376358 denotes prostate cancer
R1 T603 T604 associated_with androgen receptor,prostate cancer
R2 T603 T604 associated_with androgen receptor,prostate cancer
R3 T605 T604 associated_with MAP,prostate cancer
R4 T605 T604 associated_with MAP,prostate cancer
R5 T606 T607 associated_with HER2,breast cancer
R6 T606 T607 associated_with HER2,breast cancer
R7 T608 T609 associated_with HER2,prostate cancer
R8 T608 T609 associated_with HER2,prostate cancer
R9 T610 T611 associated_with MPK-1,prostate cancer
R10 T610 T611 associated_with MPK-1,prostate cancer
R11 T612 T613 associated_with PSA,prostate cancer
R12 T612 T613 associated_with PSA,prostate cancer

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 254-260 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 254-260 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast

DisGeNET

Id Subject Object Predicate Lexical cue
T0 134-137 gene:27352 denotes MAP
T1 148-163 disease:C0376358 denotes prostate cancer
T2 134-137 gene:27352 denotes MAP
T3 148-163 disease:C0600139 denotes prostate cancer
T4 193-197 gene:2064 denotes HER2
T5 254-267 disease:C0006142 denotes breast cancer
T6 193-197 gene:2064 denotes HER2
T7 254-267 disease:C0678222 denotes breast cancer
T8 388-392 gene:2064 denotes HER2
T9 308-323 disease:C0600139 denotes prostate cancer
T10 388-392 gene:2064 denotes HER2
T11 308-323 disease:C0376358 denotes prostate cancer
T12 507-512 gene:1843 denotes MPK-1
T13 643-658 disease:C0600139 denotes prostate cancer
T14 605-608 gene:354 denotes PSA
T15 643-658 disease:C0600139 denotes prostate cancer
T16 507-512 gene:1843 denotes MPK-1
T17 643-658 disease:C0376358 denotes prostate cancer
T18 605-608 gene:354 denotes PSA
T19 643-658 disease:C0376358 denotes prostate cancer
T20 1005-1008 gene:354 denotes PSA
T21 1111-1126 disease:C0600139 denotes prostate cancer
T22 1005-1008 gene:354 denotes PSA
T23 1111-1126 disease:C0376358 denotes prostate cancer
R1 T0 T1 associated_with MAP,prostate cancer
R2 T2 T3 associated_with MAP,prostate cancer
R3 T4 T5 associated_with HER2,breast cancer
R4 T6 T7 associated_with HER2,breast cancer
R5 T8 T9 associated_with HER2,prostate cancer
R6 T10 T11 associated_with HER2,prostate cancer
R7 T12 T13 associated_with MPK-1,prostate cancer
R8 T14 T15 associated_with PSA,prostate cancer
R9 T16 T17 associated_with MPK-1,prostate cancer
R10 T18 T19 associated_with PSA,prostate cancer
R11 T20 T21 associated_with PSA,prostate cancer
R12 T22 T23 associated_with PSA,prostate cancer

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 254-267 HP_0003002 denotes breast cancer
T2 254-267 HP_0100013 denotes breast cancer
T3 261-267 HP_0002664 denotes cancer
T4 308-323 HP_0012125 denotes prostate cancer
T5 317-323 HP_0002664 denotes cancer
T6 643-658 HP_0012125 denotes prostate cancer
T7 652-658 HP_0002664 denotes cancer
T8 1111-1126 HP_0012125 denotes prostate cancer
T9 1120-1126 HP_0002664 denotes cancer
T10 1336-1351 HP_0012125 denotes prostate cancer
T11 1345-1351 HP_0002664 denotes cancer